Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT00496431 Terminated - Hodgkin's Lymphoma Clinical Trials

phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients

Start date: May 2007
Phase: Phase 1/Phase 2
Study type: Interventional

PRIMARY OBJECTIVE - To evaluate the efficacy (according to the International Working Group response criteria for Hodgkin's Lymphomas [7, 8, 9]) of daily oral doses of ITF2357 administered to very high-risk Hodgkin's lymphoma patients. SECONDARY OBJECTIVES - To evaluate safety and tolerability of multiple oral doses of ITF2357 - To assess the proportion of patients that, after ITF2357 treatment, can undergo high-dose salvage chemotherapy with either autografting or allografting

NCT ID: NCT00494780 Completed - Clinical trials for Lymphoma, Follicular

Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients

MUNIN
Start date: June 2007
Phase: Phase 2
Study type: Interventional

To investigate the efficacy in two dose regimens of ofatumumab in combination with CHOP (cyclophosphamide,doxorubicin, vincristine,prednisolone) in previously untreated patients with Follicular Lymphoma (FL)

NCT ID: NCT00493467 Completed - Lymphoma Clinical Trials

Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

Start date: June 2006
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to find out if giving (Rituxan) rituximab with 90Y (ibritumomab tiuxetan) (90 Y Zevalin®) may be effective in treating low-grade lymphoma. The safety of this combination treatment will also be studied.

NCT ID: NCT00493454 Terminated - Lymphoma Clinical Trials

Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas

Start date: April 2006
Phase: Phase 2
Study type: Interventional

Primary Objective: - Overall Response Rate (ORR). Secondary Objectives: - The Duration of Response (DR) and Time to Treatment Progression (TTP) in all patients and in the responders. - Complete Responses (CR)/Complete Responses unconfirmed (CRu), and Partial Responses (PR). - Time to next anticancer therapy (TTNT).

NCT ID: NCT00491491 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Zevalin-beam for Aggressive Lymphoma

Start date: June 2007
Phase: Phase 3
Study type: Interventional

The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive lymphoma will reduced disease recurrence rate and improve overall and disease-free survival.

NCT ID: NCT00491127 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study it to evaluate efficacy of gemcitabine with cisplatin and dexamethasone in patients with aggressive non-Hodgkin's lymphoma who have previously progressed on first line of chemotherapy with anthracyclines.

NCT ID: NCT00490776 Terminated - Clinical trials for Cutaneous T-Cell Lymphoma

Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

Start date: July 5, 2007
Phase: Phase 2
Study type: Interventional

This study evaluated the safety and efficacy of LBH589B in adult participants with refractory/resistant Cutaneous T-Cell Lymphoma and prior Histone Deacetylase (HDAC) inhibitor therapy.

NCT ID: NCT00490529 Completed - Clinical trials for Lymphoma, Mantle-Cell

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

Start date: August 2009
Phase: Phase 2
Study type: Interventional

Mantle cell lymphoma (MCL) is a sub-type of non-Hodgkin's lymphoma (NHL) which is generally considered incurable with current therapy. Participants will receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. This vaccination may prolong the time which patients will stay in remission from their disease.

NCT ID: NCT00490490 Terminated - Clinical trials for Lymphoma, Non-Hodgkin

Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma

Start date: January 2007
Phase: Phase 2
Study type: Interventional

We hope to learn whether I-131 tositumomab combined with external beam radiation therapy is an effective means of treating relapsed, bulky non-Hodgkin's lymphoma. The purpose of the study is to determine the overall response rate with responses described as: Site-dependent and overall CR and functional CR (CR of CRu(Complete Response Unconfirmed)/PR with PET negativity), or PR rates.

NCT ID: NCT00490009 Completed - Lymphoma Clinical Trials

Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma

Start date: September 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to obtain safety and efficacy data using tositumomab or Bexxar in patients with relapsed/refractory diffuse large cell Non-Hodgkin's lymphoma (DLCL).